history

[키워드] 1:1 48 hours able to swallow accompany addition age Alexandra Algorithm ALT Antiviral Arm AST authority baseline Blinding Breastfeeding childbearing clinical clinically clinician co-morbidities co-morbidity Concomitant medication contribute control arm COVID COVID-19 COVID-19 infection COVID-19 test death defined dialysis disease dissemination doses drug duration of symptom early early stage effective Efficacy eight element Elizabeth EudraCT European excluded experimental arm Factor Favipiravir female females first positive greater haemofiltration Health hereditary xanthinuria history hospital hospitalisation hypersensitivity hypertension Hypothesis impairment in-patient Infection Infirmary information Inpatient ISARIC4C ISRCTN Loading dose maintenance dose male measure mechanism medication men metabolite negative number obesity objective offered open label Other outcome Outpatient Oxygen therapy parallel group participant Patient patients patients with COVID-19 pharmacokinetic pharmacokinetics Point positive pregnancy test pregnant Primary outcome principal investigator protocol random randomisation randomised randomised controlled trial Randomised trial receive recruit recruited recruitment reducing reference Registered Regulating reported risk risk of death Safety Sample size SARS-CoV-2 sequence severe hepatic impairment severity Severity of disease Sex Standard Standard of care standard treatment standard treatment alone status Study protocol Symptom the primary endpoint the WHO Tolerability Total treated Treatment treatment allocation treatment for COVID-19 Trial ULN undergo union university website WHO with COVID-19 women
[DOI] 10.1186/s13063-020-04891-1 PMC 바로가기 [Article Type] Letter